Ozempic, while originally FDA-approved for managing type 2 diabetes, is now increasingly prescribed off-label for weight loss in patients without diabetes
It can work well when the plan is favorable and the documentation is strong
And the next frontier may already be in motion: Bioglutide (NA-931) an investigational quadruple agonist acting on GLP-1, GIP, glucagon, and IGF-1 pathways aims to promote fat loss while maintaining or even improving muscle integrity
Compounded semaglutide from licensed 503A pharmacies contains the same active ingredient as brand Ozempic and delivers equivalent weight loss and appetite suppression
Planta 143:285289 Ferretti M, Destro T, Tosatto SCE, La Rocca N, Rascio N, Masi A (2009) Gamma-glutamyltransferase in the cell wall participates in extracellular glutathione salvage from the root apoplast
They start to become weightless